Could a gentler dose of an oral chemo drug help MDS patients avoid transfusions?
NCT ID NCT03502668
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study tested an oral drug called ASTX727 in people with lower-risk myelodysplastic syndromes (MDS), a bone marrow disorder. The goal was to see if a lower dose given over a longer schedule could improve blood cell counts and reduce the need for transfusions. The trial enrolled 160 adults and looked at safety and effectiveness in two phases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Az St-Jan Brugge-Oostende A.V.
Bruges, Belgium
-
BRCR Medical Center Inc.
Plantation, Florida, 33324, United States
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Univeristario y Politecnico La Fe Servicio de Hematologia
Valencia, 46026, Spain
-
Hospital Universitario Vall d Hebron
Barcelona, Spain
-
Indiana University Health Hospital - Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
-
London Regional Cancer Center
London, Ontario, N6A 5W9, Canada
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Moffitt Cancer Center Site#507
Tampa, Florida, 33612, United States
-
Oregon Health and Science University Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Texas Oncology - Tyler
Tyler, Texas, 75702, United States
-
The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division)
Bethesda, Maryland, 20817, United States
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universita degli Studi di Firenze
Florence, Italy
-
Universitaetsklinikum Freiburg Site#703
Freiburg im Breisgau, 79106, Germany
-
University of Alberta Hospital - Hematology Research
Edmonton, T6G 2B7, Canada
-
University of Colorado, Anschutz Cancer Pavilion
Aurora, Colorado, 80045, United States
-
University of Kansas Clinical Research Center
Westwood, Kansas, 66205, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
Universitätsklinikum Halle
Halle, 06120, Germany
-
Vanderbilt University Medical Center - Hematology-Oncology
Nashville, Tennessee, 37232, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
-
ZNA - Campus Middelheim
Antwerp, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASTX727 (oral decitabine and cedazuridine)
What this could lead to
If successful, this could offer a more convenient oral treatment option for people with lower-risk MDS, potentially improving blood cell counts and reducing transfusion needs.
What could go wrong
This is an early-phase trial with small groups, so results may not confirm benefit. The drug can cause side effects like low blood counts or infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.